Project description:Radiation-induced enteritis (RIE) is a common and severe adverse effect of radiotherapy for abdominal and pelvic tumors, with limited effective treatments. We previously demonstrated that intravenous immunoglobulin (IVIg) alleviates radiation toxicity, but its mechanism of action on intestinal stem cell (ISC) regeneration remains unclear. Here, we performed RNA-seq on the small intestine of mice with radiation-induced enteritis to investigate the transcriptomic changes induced by IVIg treatment. Total abdominal irradiation (TAI, 12 Gy) was performed on C57BL/6J mice, followed by intravenous administration of IVIg (500 mg/kg) within 1 h after irradiation. Jejunal tissues were collected on Day 3 post-irradiation for RNA-seq analysis. Our results show that IVIg treatment significantly altered the expression of genes related to cell proliferation, inflammation, oxidative stress, and the Wnt/β-catenin signaling pathway, which is critical for ISC maintenance and regeneration. These data provide a molecular basis for the radioprotective effect of IVIg in mitigating RIE, supporting its potential as a therapeutic candidate for this condition.
Project description:To investigate the effect of IVIG and desialylated IVIG on the activation of plasmacytoid dendritic cells (pDCs). Human primary plasmacytoid dendritic cells were treated with TLR stimulation together with or without IVIG or desialylated IVIG, and the change of genes were analyzed. Primary human pDCs were preincubated with or without 10mg/ml IVIG or desialylated IVIG followed by stimulation with CpG overnight. The different genes between IVIG+CpG and desialylated IVIG+CpG were analyzed.
Project description:Identification of IVIg regulated genes in human peripheral blood monocytes by gene expression analysis before and after IVIg infusion in CVID patients
Project description:Identification of IVIg regulated genes in human peripheral blood B cells by gene expression analysis before and after IVIg infusion in CVID patients
Project description:We compared the abundance of gene transcripts of whole blood RNA between IVIG-resistant and –responsive KD patients to identify biomarkers that might differentiate between these two groups and to generate new targets for therapies in IVIG-resistant KD patients.
Project description:Intravenous immunoglobulin (IVIG) is a first-line drug prepared from human plasma for the treatment of autoimmune diseases (AID), especially immune thrombocytopenia (ITP). Since significant differences exist in protein types and expression levels between male and female plasma, and the prevalence of autoimmune diseases varies between sexes. The present study seeks to explore potential variations in IVIG sourced from distinct sex-specific plasma (DSP-IVIG), including IVIG sourced from female plasma (F-IVIG), IVIG sourced from male plasma (M-IVIG), and IVIG sourced from a blend of male and female plasma (Mix-IVIG). We investigate whether these IVIG variants exhibit different effects in the treatment of ITP. To address this question, we established an ITP mouse model treated with DSP IVIG.
Project description:To investigate the role of Dectin-1 and FcgRIIb on monocytes as signaling hubs for IVIg Immunoglobulin G (IgG) antibodies are major drivers of inflammation during infectious and autoimmune diseases. In pooled serum IgG (IVIg), however, antibodies have a potent immunomodulatory and anti-inflammatory activity, but how this is mediated is unclear. We studied IgG-dependent initiation of resolution of inflammation in cytokine- and autoantibody-driven models of rheumatoid arthritis and found IVIg sialylation inhibited joint inflammation while inhibition of osteoclastogenesis was sialic acid-independent. Instead, IVIg-dependent inhibition of osteoclastogenesis was abrogated in mice lacking receptors Dectin-1 or FcgRIIb. Atomistic molecular dynamics simulations and super-resolution microscopy revealed that Dectin-1 promoted FcgRIIb membrane conformations that allowed productive IgG binding and enhanced interactions with mouse and human IgG subclasses. IVIg reprogrammed monocytes via FcgRIIb-dependent signaling that required Dectin-1.
Project description:Intravenous immunoglobulin (IVIg) is used to treat mucous membrane pemphigoid (MMP), although its therapeutic effectivity is not sufficiently supported by randomized controlled clinical trials and its mode of action is only insufficiently understood. We have examined the effect of IVIg in a mouse model of anti-laminin 332 MMP and found that IVIg ameliorates both cutaneous and mucosal inflammatory lesions. Our investigation into the modes of action of IVIg in MMP indicated effective antiinflammatory mechanisms beyond the enhanced degradation of IgG mediated through inhibition of the neonatal Fc receptor. Our results suggest that IVIg curbs the activation of neutrophils at several levels. This includes a direct, immediate inhibitory effect on neutrophil activation by immune complexes but not C5a which blunts the release of reactive oxygen species and leukotriene B4 from neutrophils. IVIg also suppresses the formation of neutrophil extracellular traps in response to Ca2+ ionophore. In vivo treatment with IVIg altered the transcriptome of blood leukocytes and bone marrow neutrophils towards less proinflammatory phenotypes. Collectively, our results support the effectivity of IVIg in the treatment of MMP and indicate that effects on neutrophils at multiple levels may significantly contribute to its therapeutic effects.
Project description:Identification of IVIg regulated genes in human peripheral blood monocytes by gene expression analysis before and after IVIg infusion in CVID patients